This result was consistent in the subgroups of patients with stage I-III CRC disease and colon cancer and, interestingly, also in the subgroup of patients with rectal cancer, in which negative ERα expression showed the greatest benefit, with a reduction in overall mortality of 80% (Fig. 1B-D). This evidence concerns the gene ESR1 and rectal cancer.